<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Mutat</journal-id><journal-id journal-id-type="iso-abbrev">Hum. Mutat</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1098-1004</journal-id><journal-id journal-id-type="publisher-id">HUMU</journal-id><journal-title-group><journal-title>Human Mutation</journal-title></journal-title-group><issn pub-type="ppub">1059-7794</issn><issn pub-type="epub">1098-1004</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6175364</article-id><article-id pub-id-type="doi">10.1002/humu.23567</article-id><article-id pub-id-type="publisher-id">HUMU23567</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Elucidating the genetic architecture of Adams&#8211;Oliver syndrome in a large European cohort</article-title><alt-title alt-title-type="left-running-head">MEESTER et&#160;al.</alt-title></title-group><contrib-group><contrib id="humu23567-cr-0001" contrib-type="author"><name><surname>Meester</surname><given-names>Josephina A.N.</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8516-5856</contrib-id><xref ref-type="aff" rid="humu23567-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="humu23567-cr-0002" contrib-type="author"><name><surname>Sukalo</surname><given-names>Maja</given-names></name><xref ref-type="aff" rid="humu23567-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="humu23567-cr-0003" contrib-type="author"><name><surname>Schr&#246;der</surname><given-names>Kim C.</given-names></name><xref ref-type="aff" rid="humu23567-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="humu23567-cr-0004" contrib-type="author"><name><surname>Schanze</surname><given-names>Denny</given-names></name><xref ref-type="aff" rid="humu23567-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="humu23567-cr-0005" contrib-type="author"><name><surname>Baynam</surname><given-names>Gareth</given-names></name><xref ref-type="aff" rid="humu23567-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="humu23567-aff-0004">
<sup>4</sup>
</xref><xref ref-type="aff" rid="humu23567-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="humu23567-cr-0006" contrib-type="author"><name><surname>Borck</surname><given-names>Guntram</given-names></name><xref ref-type="aff" rid="humu23567-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="humu23567-cr-0007" contrib-type="author"><name><surname>Bramswig</surname><given-names>Nuria C.</given-names></name><xref ref-type="aff" rid="humu23567-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="humu23567-cr-0008" contrib-type="author"><name><surname>Duman</surname><given-names>Duygu</given-names></name><xref ref-type="aff" rid="humu23567-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="humu23567-cr-0009" contrib-type="author"><name><surname>Gilbert&#8208;Dussardier</surname><given-names>Brigitte</given-names></name><xref ref-type="aff" rid="humu23567-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="humu23567-cr-0010" contrib-type="author"><name><surname>Holder&#8208;Espinasse</surname><given-names>Muriel</given-names></name><xref ref-type="aff" rid="humu23567-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="humu23567-cr-0011" contrib-type="author"><name><surname>Itin</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="humu23567-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="humu23567-cr-0012" contrib-type="author"><name><surname>Johnson</surname><given-names>Diana S.</given-names></name><xref ref-type="aff" rid="humu23567-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="humu23567-cr-0013" contrib-type="author"><name><surname>Joss</surname><given-names>Shelagh</given-names></name><xref ref-type="aff" rid="humu23567-aff-0013">
<sup>13</sup>
</xref></contrib><contrib id="humu23567-cr-0014" contrib-type="author"><name><surname>Koillinen</surname><given-names>Hannele</given-names></name><xref ref-type="aff" rid="humu23567-aff-0014">
<sup>14</sup>
</xref></contrib><contrib id="humu23567-cr-0015" contrib-type="author"><name><surname>McKenzie</surname><given-names>Fiona</given-names></name><xref ref-type="aff" rid="humu23567-aff-0015">
<sup>15</sup>
</xref></contrib><contrib id="humu23567-cr-0016" contrib-type="author"><name><surname>Morton</surname><given-names>Jenny</given-names></name><xref ref-type="aff" rid="humu23567-aff-0016">
<sup>16</sup>
</xref></contrib><contrib id="humu23567-cr-0017" contrib-type="author"><name><surname>Nelle</surname><given-names>Heike</given-names></name><xref ref-type="aff" rid="humu23567-aff-0017">
<sup>17</sup>
</xref></contrib><contrib id="humu23567-cr-0018" contrib-type="author"><name><surname>Reardon</surname><given-names>Willie</given-names></name><xref ref-type="aff" rid="humu23567-aff-0018">
<sup>18</sup>
</xref></contrib><contrib id="humu23567-cr-0019" contrib-type="author"><name><surname>Roll</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="humu23567-aff-0019">
<sup>19</sup>
</xref></contrib><contrib id="humu23567-cr-0020" contrib-type="author"><name><surname>Salih</surname><given-names>Mustafa A.</given-names></name><xref ref-type="aff" rid="humu23567-aff-0020">
<sup>20</sup>
</xref></contrib><contrib id="humu23567-cr-0021" contrib-type="author"><name><surname>Savarirayan</surname><given-names>Ravi</given-names></name><xref ref-type="aff" rid="humu23567-aff-0021">
<sup>21</sup>
</xref></contrib><contrib id="humu23567-cr-0022" contrib-type="author"><name><surname>Scurr</surname><given-names>Ingrid</given-names></name><xref ref-type="aff" rid="humu23567-aff-0022">
<sup>22</sup>
</xref></contrib><contrib id="humu23567-cr-0023" contrib-type="author"><name><surname>Splitt</surname><given-names>Miranda</given-names></name><xref ref-type="aff" rid="humu23567-aff-0023">
<sup>23</sup>
</xref></contrib><contrib id="humu23567-cr-0024" contrib-type="author"><name><surname>Thompson</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="humu23567-aff-0024">
<sup>24</sup>
</xref><xref ref-type="aff" rid="humu23567-aff-0025">
<sup>25</sup>
</xref></contrib><contrib id="humu23567-cr-0025" contrib-type="author"><name><surname>Titheradge</surname><given-names>Hannah</given-names></name><xref ref-type="aff" rid="humu23567-aff-0016">
<sup>16</sup>
</xref></contrib><contrib id="humu23567-cr-0026" contrib-type="author"><name><surname>Travers</surname><given-names>Colm P.</given-names></name><xref ref-type="aff" rid="humu23567-aff-0026">
<sup>26</sup>
</xref></contrib><contrib id="humu23567-cr-0027" contrib-type="author"><name><surname>Van Maldergem</surname><given-names>Lionel</given-names></name><xref ref-type="aff" rid="humu23567-aff-0027">
<sup>27</sup>
</xref></contrib><contrib id="humu23567-cr-0028" contrib-type="author"><name><surname>Whiteford</surname><given-names>Margo</given-names></name><xref ref-type="aff" rid="humu23567-aff-0028">
<sup>28</sup>
</xref></contrib><contrib id="humu23567-cr-0029" contrib-type="author"><name><surname>Wieczorek</surname><given-names>Dagmar</given-names></name><xref ref-type="aff" rid="humu23567-aff-0029">
<sup>29</sup>
</xref></contrib><contrib id="humu23567-cr-0030" contrib-type="author"><name><surname>Vandeweyer</surname><given-names>Geert</given-names></name><xref ref-type="aff" rid="humu23567-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="humu23567-cr-0031" contrib-type="author"><name><surname>Trembath</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="humu23567-aff-0030">
<sup>30</sup>
</xref></contrib><contrib id="humu23567-cr-0032" contrib-type="author"><name><surname>Van Laer</surname><given-names>Lut</given-names></name><xref ref-type="aff" rid="humu23567-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="humu23567-cr-0033" contrib-type="author"><name><surname>Loeys</surname><given-names>Bart L.</given-names></name><xref ref-type="aff" rid="humu23567-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="humu23567-cr-0034" contrib-type="author"><name><surname>Zenker</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="humu23567-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="humu23567-cr-0035" contrib-type="author"><name><surname>Southgate</surname><given-names>Laura</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2090-1450</contrib-id><xref ref-type="aff" rid="humu23567-aff-0030">
<sup>30</sup>
</xref><xref ref-type="aff" rid="humu23567-aff-0031">
<sup>31</sup>
</xref></contrib><contrib id="humu23567-cr-0036" contrib-type="author" corresp="yes"><name><surname>Wuyts</surname><given-names>Wim</given-names></name><address><email>wim.wuyts@uantwerpen.be</email></address><xref ref-type="aff" rid="humu23567-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="humu23567-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Center of Medical Genetics</named-content>
<institution>University of Antwerp and Antwerp University Hospital</institution>
<named-content content-type="city">Antwerp</named-content>
<country country="BE">Belgium</country>
</aff><aff id="humu23567-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Institute of Human Genetics</named-content>
<institution>University Hospital Magdeburg</institution>
<named-content content-type="city">Magdeburg</named-content>
<country country="DE">Germany</country>
</aff><aff id="humu23567-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Genetic Services of Western Australia and the Western Australian Register of Developmental Anomalies</named-content>
<institution>King Edward Memorial Hospital</institution>
<named-content content-type="city">Perth</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu23567-aff-0004">
<label><sup>4</sup></label>
<institution>Telethon Kids Institute</institution>
<named-content content-type="city">Perth</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu23567-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">School of Paediatrics and Child Health</named-content>
<institution>University of Western Australia</institution>
<named-content content-type="city">Perth</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu23567-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Institute of Human Genetics</named-content>
<institution>University of Ulm</institution>
<named-content content-type="city">Ulm</named-content>
<country country="DE">Germany</country>
</aff><aff id="humu23567-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Institut f&#252;r Humangenetik</named-content>
<institution>Universit&#228;tsklinikum Essen, Universit&#228;t Duisburg&#8208;Essen</institution>
<named-content content-type="city">Essen</named-content>
<country country="DE">Germany</country>
</aff><aff id="humu23567-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">Division of Pediatric Genetics</named-content>
<institution>Ankara University School of Medicine</institution>
<named-content content-type="city">Ankara</named-content>
<country country="TR">Turkey</country>
</aff><aff id="humu23567-aff-0009">
<label><sup>9</sup></label>
<named-content content-type="organisation-division">Service de G&#233;n&#233;tique, CHU de Poitiers</named-content>
<institution>University of Poitiers</institution>
<named-content content-type="city">Poitiers</named-content>
<country country="FR">France</country>
</aff><aff id="humu23567-aff-0010">
<label><sup>10</sup></label>
<named-content content-type="organisation-division">Guy's Regional Genetics Service</named-content>
<institution>Guy's and St Thomas' NHS Foundation Trust</institution>
<named-content content-type="city">London</named-content>
<country country="GB">United Kingdom</country>
</aff><aff id="humu23567-aff-0011">
<label><sup>11</sup></label>
<named-content content-type="organisation-division">Department of Dermatology</named-content>
<institution>Basel University Hospital</institution>
<named-content content-type="city">Basel</named-content>
<country country="CH">Switzerland</country>
</aff><aff id="humu23567-aff-0012">
<label><sup>12</sup></label>
<named-content content-type="organisation-division">Department of Clinical Genetics</named-content>
<institution>Sheffield Children's NHS Foundation Trust</institution>
<named-content content-type="city">Sheffield</named-content>
<country country="GB">United Kingdom</country>
</aff><aff id="humu23567-aff-0013">
<label><sup>13</sup></label>
<named-content content-type="organisation-division">West of Scotland Clinical Genetics Service</named-content>
<institution>Queen Elizabeth University Hospital</institution>
<named-content content-type="city">Glasgow</named-content>
<country country="GB">United Kingdom</country>
</aff><aff id="humu23567-aff-0014">
<label><sup>14</sup></label>
<named-content content-type="organisation-division">Department of Clinical Genetics</named-content>
<institution>Helsinki University Hospital</institution>
<named-content content-type="city">Helsinki</named-content>
<country country="FI">Finland</country>
</aff><aff id="humu23567-aff-0015">
<label><sup>15</sup></label>
<named-content content-type="organisation-division">Genetic Services of Western Australia</named-content>
<institution>King Edward Memorial Hospital for Women</institution>
<named-content content-type="city">Subiaco</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu23567-aff-0016">
<label><sup>16</sup></label>
<named-content content-type="organisation-division">West Midlands Regional Clinical Genetics Service and Birmingham Health Partners</named-content>
<institution>Birmingham Women's Hospital NHS Foundation Trust</institution>
<named-content content-type="city">Birmingham</named-content>
<country country="GB">United Kingdom</country>
</aff><aff id="humu23567-aff-0017">
<label><sup>17</sup></label>
<institution>MVZ f&#252;r Pr&#228;natalmedizin und Genetik</institution>
<named-content content-type="city">N&#252;rnberg</named-content>
<country country="DE">Germany</country>
</aff><aff id="humu23567-aff-0018">
<label><sup>18</sup></label>
<named-content content-type="organisation-division">Clinical Genetics</named-content>
<institution>National Maternity Hospital</institution>
<named-content content-type="city">Dublin</named-content>
<country country="IE">Ireland</country>
</aff><aff id="humu23567-aff-0019">
<label><sup>19</sup></label>
<named-content content-type="organisation-division">Abteilung Neonatologie und P&#228;diatrische Intensivmedizin, Vestische Kinder&#8208; und Jugendklinik Datteln</named-content>
<institution>Universit&#228;t Witten/Herdecke</institution>
<named-content content-type="city">Datteln</named-content>
<country country="DE">Germany</country>
</aff><aff id="humu23567-aff-0020">
<label><sup>20</sup></label>
<named-content content-type="organisation-division">Division of Pediatric Neurology, Department of Pediatrics</named-content>
<institution>King Khalid University Hospital and College of Medicine, King Saud University</institution>
<named-content content-type="city">Riyadh</named-content>
<country country="SA">Saudi Arabia</country>
</aff><aff id="humu23567-aff-0021">
<label><sup>21</sup></label>
<named-content content-type="organisation-division">Victorian Clinical Genetics Services, Murdoch Children's Research Institute</named-content>
<institution>and the University of Melbourne</institution>
<named-content content-type="city">Melbourne</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu23567-aff-0022">
<label><sup>22</sup></label>
<named-content content-type="organisation-division">Bristol Genetics Service, University Hospitals Bristol NHS Foundation Trust</named-content>
<institution>St Michael's Hospital</institution>
<named-content content-type="city">Bristol</named-content>
<country country="GB">United Kingdom</country>
</aff><aff id="humu23567-aff-0023">
<label><sup>23</sup></label>
<named-content content-type="organisation-division">Northern Genetics Service</named-content>
<institution>Newcastle upon Tyne Hospitals NHS Foundation Trust</institution>
<named-content content-type="city">Newcastle upon Tyne</named-content>
<country country="GB">United Kingdom</country>
</aff><aff id="humu23567-aff-0024">
<label><sup>24</sup></label>
<named-content content-type="organisation-division">South Australian Clinical Genetics Service, North Adelaide, South Australia, Australia</named-content>
<institution>SA Clinical Genetics Service, SA Pathology at the Women's and Children's Hospital</institution>
<named-content content-type="city">North Adelaide</named-content>
<named-content content-type="country-part">SA</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu23567-aff-0025">
<label><sup>25</sup></label>
<named-content content-type="organisation-division">School of Medicine</named-content>
<institution>University of Adelaide</institution>
<named-content content-type="street">North Terrace</named-content>
<named-content content-type="city">Adelaide</named-content>
<named-content content-type="country-part">SA</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu23567-aff-0026">
<label><sup>26</sup></label>
<named-content content-type="organisation-division">Division of Neonatology</named-content>
<institution>University of Alabama at Birmingham</institution>
<named-content content-type="city">Birmingham</named-content>
<country country="US">USA</country>
</aff><aff id="humu23567-aff-0027">
<label><sup>27</sup></label>
<named-content content-type="organisation-division">Centre de G&#233;n&#233;tique Humaine</named-content>
<institution>Universit&#233; de Franche&#8208;Comt&#233;</institution>
<named-content content-type="city">Besan&#231;on</named-content>
<country country="FR">France</country>
</aff><aff id="humu23567-aff-0028">
<label><sup>28</sup></label>
<named-content content-type="organisation-division">West of Scotland Genetic Services</named-content>
<institution>Queen Elizabeth University Hospital</institution>
<named-content content-type="city">Glasgow</named-content>
<country country="GB">United Kingdom</country>
</aff><aff id="humu23567-aff-0029">
<label><sup>29</sup></label>
<named-content content-type="organisation-division">Institute of Human Genetics, Medical Faculty</named-content>
<institution>Heinrich Heine University</institution>
<named-content content-type="city">D&#252;sseldorf</named-content>
<country country="DE">Germany</country>
</aff><aff id="humu23567-aff-0030">
<label><sup>30</sup></label>
<named-content content-type="organisation-division">Division of Genetics &amp; Molecular Medicine, King's College London</named-content>
<institution>Faculty of Life Sciences &amp; Medicine, Guy's Hospital</institution>
<named-content content-type="city">London</named-content>
<country country="GB">United Kingdom</country>
</aff><aff id="humu23567-aff-0031">
<label><sup>31</sup></label>
<named-content content-type="organisation-division">Molecular and Clinical Sciences Research Institute</named-content>
<institution>St George's University of London</institution>
<named-content content-type="city">London</named-content>
<country country="GB">United Kingdom</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Wim Wuyts, Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium.<break/>Email: <email>wim.wuyts@uantwerpen.be</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2018</year></pub-date><volume>39</volume><issue>9</issue><issue-id pub-id-type="doi">10.1002/humu.2018.39.issue-9</issue-id><fpage>1246</fpage><lpage>1261</lpage><history><date date-type="received"><day>23</day><month>2</month><year>2018</year></date><date date-type="rev-recd"><day>15</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2018</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 Wiley Periodicals, Inc. <copyright-statement>--><copyright-statement content-type="article-copyright">&#169; 2018 The Authors. <italic>Human Mutation</italic> published by Wiley Periodicals, Inc.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:HUMU-39-1246.pdf"/><abstract><title>Abstract</title><p>Adams&#8211;Oliver syndrome (AOS) is a rare developmental disorder, characterized by scalp aplasia cutis congenita (ACC) and transverse terminal limb defects (TTLD). Autosomal dominant forms of AOS are linked to mutations in <italic>ARHGAP31</italic>, <italic>DLL4</italic>, <italic>NOTCH1</italic> or <italic>RBPJ</italic>, while <italic>DOCK6</italic> and <italic>EOGT</italic> underlie autosomal recessive inheritance. Data on the frequency and distribution of mutations in large cohorts are currently limited. The purpose of this study was therefore to comprehensively examine the genetic architecture of AOS in an extensive cohort. Molecular diagnostic screening of 194 AOS/ACC/TTLD probands/families was conducted using next&#8208;generation and/or capillary sequencing analyses. In total, we identified 63 (likely) pathogenic mutations, comprising 56 distinct and 22 novel mutations, providing a molecular diagnosis in 30% of patients. Taken together with previous reports, these findings bring the total number of reported disease variants to 63, with a diagnostic yield of 36% in familial cases. <italic>NOTCH1</italic>&#160;is the major contributor, underlying 10% of AOS/ACC/TTLD cases, with <italic>DLL4</italic> (6%), <italic>DOCK6</italic> (6%), <italic>ARHGAP31</italic> (3%), <italic>EOGT</italic> (3%), and <italic>RBPJ</italic> (2%) representing additional causality in this cohort. We confirm the relevance of genetic screening across the AOS/ACC/TTLD spectrum, highlighting preliminary but important genotype&#8211;phenotype correlations. This cohort offers potential for further gene identification to address missing heritability.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="humu23567-kwd-0001">Adams&#8211;Oliver syndrome</kwd><kwd id="humu23567-kwd-0002">genetics</kwd><kwd id="humu23567-kwd-0003">mutation screening</kwd><kwd id="humu23567-kwd-0004">Notch signaling</kwd><kwd id="humu23567-kwd-0005">Rho GTPase
</kwd></kwd-group><funding-group><award-group><funding-source>King Saud University</funding-source></award-group><award-group><funding-source>Wellcome Trust</funding-source><award-id>204809/Z/16/Z</award-id></award-group><award-group><funding-source>Hartstichting</funding-source><award-id>2013T093</award-id></award-group><award-group><funding-source>Universiteit Antwerpen</funding-source><award-id>Lanceringsproject</award-id></award-group><award-group><funding-source>National Institute for Health Research</funding-source></award-group><award-group><funding-source>Fonds Wetenschappelijk Onderzoek</funding-source><award-id>11Y5817N</award-id><award-id>12D1717N</award-id><award-id>G.0221.12</award-id></award-group><award-group><funding-source>Fritz Thyssen Stiftung</funding-source><award-id>AZ 10.15.2.040MN</award-id></award-group><award-group><funding-source>Fondation Leducq</funding-source><award-id>MIBAVA&#8208;Leducq 12CVD03</award-id></award-group><award-group><funding-source>European Research Council</funding-source><award-id>ERC&#8208;StG&#8208;2012&#8208;30972&#8208;BRAVE</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="2"/><page-count count="16"/><word-count count="8843"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>humu23567</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.0 mode:remove_FC converted:08.10.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="humu23567-cit-0034">
<string-name>
<surname>Meester</surname>
<given-names>JAN</given-names>
</string-name>, <string-name>
<surname>Sukalo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schr&#246;der</surname>
<given-names>KC</given-names>
</string-name>, et&#160;al. <article-title>Elucidating the genetic architecture of Adams&#8211;Oliver syndrome in a large European cohort</article-title>. <source xml:lang="en">Human Mutation</source>. <year>2018</year>;<volume>39</volume>:<fpage>1246</fpage>&#8211;<lpage>1261</lpage>. <pub-id pub-id-type="doi">10.1002/humu.23567</pub-id>
<pub-id pub-id-type="pmid">29924900</pub-id></mixed-citation>
</p><fn-group><fn id="humu23567-note-0001"><p>The first two authors contributed equally to this work.</p></fn><fn id="humu23567-note-0002"><p>The last three authors jointly supervised this work.</p></fn><fn id="humu23567-note-0003"><p>The copyright line for this article was changed on August 30, 2018 after original online publication.</p></fn></fn-group></notes></front><body><sec id="humu23567-sec-0010"><label>1</label><title>INTRODUCTION</title><p>Adams&#8211;Oliver syndrome (AOS) is a rare developmental disorder characterized by both aplasia cutis congenita (ACC) of the scalp and transverse terminal limb defects (TTLD), including hypoplastic nails, brachydactyly, oligodactyly, and amputation defects (Adams &amp; Oliver, <xref rid="humu23567-bib-0001" ref-type="ref">1945</xref>; Snape et&#160;al., <xref rid="humu23567-bib-0028" ref-type="ref">2009</xref>). Additional abnormalities affect the cardiovascular and neurological systems. Approximately 20% of AOS patients have congenital heart defects, including atrial septal defect (ASD), ventricular septal defect (VSD), tetralogy of Fallot (TOF), as well as valvular and ventricular abnormalities. A similar proportion is affected by vascular anomalies, for example, cutis marmorata telangiectatica congenita (CMTC). Neurological abnormalities occur less frequently and include intracranial abnormalities (e.g., calcification, cortical dysplasia, and gliosis), developmental delay, intellectual disability, epilepsy, and microcephaly (Digilio, Marino, Baban, &amp; Dallapiccola, <xref rid="humu23567-bib-0008" ref-type="ref">2015</xref>; Lehman, Wuyts, &amp; Patel, <xref rid="humu23567-bib-0015" ref-type="ref">2016</xref>; Snape et&#160;al., <xref rid="humu23567-bib-0028" ref-type="ref">2009</xref>).</p><p>Multiple causative genes have been discovered for AOS over the past few years. Heterozygous mutations in <italic>ARHGAP31</italic> (MIM# 100300), <italic>RBPJ</italic> (MIM# 614814), <italic>NOTCH1</italic> (MIM# 616028), or <italic>DLL4</italic> (MIM# 616589) have been described in autosomal dominant and sporadic cases, while autosomal recessive forms of AOS may be due to biallelic mutations in <italic>DOCK6</italic> (MIM# 614219) or <italic>EOGT</italic> (MIM# 615297) (Cohen et&#160;al., <xref rid="humu23567-bib-0006" ref-type="ref">2014</xref>; Hassed et&#160;al., <xref rid="humu23567-bib-0010" ref-type="ref">2012</xref>; Lehman et&#160;al., <xref rid="humu23567-bib-0014" ref-type="ref">2014</xref>; Meester et&#160;al., <xref rid="humu23567-bib-0020" ref-type="ref">2015</xref>; Shaheen et&#160;al., <xref rid="humu23567-bib-0027" ref-type="ref">2011</xref>, 2013; Southgate et&#160;al., <xref rid="humu23567-bib-0029" ref-type="ref">2011</xref>, <xref rid="humu23567-bib-0030" ref-type="ref">2015</xref>; Stittrich et&#160;al., <xref rid="humu23567-bib-0031" ref-type="ref">2014</xref>; Sukalo et&#160;al., <xref rid="humu23567-bib-0032" ref-type="ref">2015</xref>). The NOTCH pathway plays a major role in AOS pathogenesis, with four causal genes (<italic>RBPJ</italic>, <italic>NOTCH1</italic>, <italic>DLL4</italic>, and <italic>EOGT</italic>) involved in Notch signaling. Specifically, DLL4 is a ligand of the Notch receptors (NOTCH1&#8208;4), while RBPJ is the major transcriptional regulator for Notch signaling, modulated by its transcriptional complex with the Notch intracellular domain, which is cleaved upon activation of the pathway (Bray, <xref rid="humu23567-bib-0005" ref-type="ref">2006</xref>). EOGT is an epidermal growth factor (EGF) domain&#8208;specific O&#8208;linked <italic>N</italic>&#8208;acetylglucosamine transferase and, although its function remains relatively poorly characterized in humans, it has been shown to act on EGF domain&#8211;containing proteins, including the Notch receptors in mammals (Sakaidani et&#160;al., <xref rid="humu23567-bib-0023" ref-type="ref">2012</xref>). By contrast, <italic>ARHGAP31</italic> and <italic>DOCK6</italic> are not directly linked to Notch signaling, but instead encode regulatory proteins that specifically control the activity of the Rho GTPases RAC1 and CDC42, which are important for the maintenance of the actin cytoskeleton (Southgate et&#160;al., <xref rid="humu23567-bib-0029" ref-type="ref">2011</xref>).</p><p>AOS has an estimated frequency of one affected individual per 225,000 live births (Martinez&#8208;Frias et&#160;al., <xref rid="humu23567-bib-0019" ref-type="ref">1996</xref>). Due to the rarity of this disorder and relatively recent identification of causal genes, the percentage of AOS cases attributable to each of the established AOS genes in large cohorts remains unclear. Importantly, gaining a better understanding of potential genotype&#8211;phenotype correlations in this condition may identify &#8220;at&#8208;risk&#8221; individuals who have an increased likelihood of developing additional medical complications. Here, we report on the molecular characterization of an extensive cohort of AOS/ACC/TTLD probands and their family members, providing further clarity with regard to the interpretation of identified variants and potential for improved molecular diagnosis and clinical management of these patients.</p></sec><sec id="humu23567-sec-0020"><label>2</label><title>MATERIALS AND METHODS</title><sec id="humu23567-sec-0030"><label>2.1</label><title>Patient cohort</title><p>All patients and families were recruited through the European AOS Consortium, and all participants provided informed written consent to participate in the study. The study was approved by the appropriate institutional ethics review boards. Patients were diagnosed according to the diagnostic criteria proposed by Snape et&#160;al. (<xref rid="humu23567-bib-0028" ref-type="ref">2009</xref>). Specifically, the presence of two major criteria (TTLD, ACC, or a documented family history) or one major and one minor feature (CMTC, congenital cardiac defect, or vascular anomaly) was considered strongly indicative of AOS. Patients with ACC or TTLD in the absence of any associated family history of AOS or other syndromic features were classified as isolated ACC or isolated TTLD, respectively. Based on the diagnostic criteria proposed by Lehman et&#160;al. (<xref rid="humu23567-bib-0015" ref-type="ref">2016</xref>), the presence of a (likely) pathogenic variant in an autosomal dominant AOS&#8208;related gene or a biallelic (likely) pathogenic variant in an autosomal recessive AOS&#8208;related gene was also considered a major criterion. A total of 194 families/probands were included in this study; only the proband for each family was used for the calculation of frequencies, yields, and counts. All affected individuals of the family were taken into consideration for description of the clinical features.</p></sec><sec id="humu23567-sec-0040"><label>2.2</label><title>Sequencing</title><p>All AOS/ACC/TTLD patients were screened for mutations in the six established genes (<italic>ARHGAP31</italic>: NM_020754.3; <italic>DLL4</italic>: NM_019074.3; <italic>DOCK6</italic>: NM_020812.3; <italic>EOGT</italic>: NM_001278689.1; <italic>NOTCH1</italic>: NM_017617.4; <italic>RBPJ</italic>: NM_005349.3). The majority of the samples were sequenced by targeted next&#8208;generation resequencing (<italic>n</italic>&#160;=&#160;140) using either the HaloPlex Target Enrichment System (Agilent Technologies, Santa Clara, CA) as described previously (Meester et&#160;al., <xref rid="humu23567-bib-0020" ref-type="ref">2015</xref>), or a TruSeq Custom Amplicon Panel (Illumina, San Diego, CA) followed by sequencing on a MiSeq system (Illumina, San Diego, CA) with 150&#160;bp paired&#8208;end reads. Sequence data obtained from the TruSeq Custom Amplicon Panel were analyzed using Illumina's VariantStudio Data Analysis Software v3.0. GRCh37 was used as the reference human genome build. The remaining patients were screened by either whole&#8208;exome sequencing (WES, <italic>n</italic>&#160;=&#160;28) or Sanger sequencing (<italic>n</italic>&#160;=&#160;26) as previously described (Southgate et&#160;al., <xref rid="humu23567-bib-0030" ref-type="ref">2015</xref>; Sukalo et&#160;al., <xref rid="humu23567-bib-0032" ref-type="ref">2015</xref>). ANNOVAR (Wang, Li, &amp; Hakonarson, <xref rid="humu23567-bib-0033" ref-type="ref">2010</xref>) dbNSFPv3.0.a (Liu, Jian, &amp; Boerwinkle, <xref rid="humu23567-bib-0016" ref-type="ref">2011</xref>) annotation was used for <italic>in silico</italic> prediction scores, including MutationTaster (Schwarz, Cooper, Schuelke, &amp; Seelow, <xref rid="humu23567-bib-0025" ref-type="ref">2014</xref>), SIFT (Kumar, Henikoff, &amp; Ng, <xref rid="humu23567-bib-0013" ref-type="ref">2009</xref>), PolyPhen2 hvar (Adzhubei et&#160;al., <xref rid="humu23567-bib-0002" ref-type="ref">2010</xref>), and CADD (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S1</xref>) (Kircher et&#160;al., <xref rid="humu23567-bib-0012" ref-type="ref">2014</xref>). Alamut (v2.8.1) was used for <italic>in silico</italic> splicing predictions, including SpliceSiteFinder&#8208;like, MaxEntScan, NNSPLICE, GeneSplicer, and Human Splicing Finder (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S2</xref>). After identification of a likely pathogenic variant by Sanger sequencing of single genes, no further screening of the remaining AOS genes was performed. All observed mutations were confirmed by conventional Sanger sequencing on an independent sample.</p></sec><sec id="humu23567-sec-0050"><label>2.3</label><title>Variant classification</title><p>Variants are classified according to the American College of Medical Genetics (ACMG) guidelines (Richards et&#160;al., <xref rid="humu23567-bib-0022" ref-type="ref">2015</xref>). However, we have used a few additional gene&#8208;specific criteria, in consideration of the pathogenic mechanisms involved in AOS. First, all protein&#8208;truncating mutations in the last exon of <italic>ARGHAP31</italic> were classified as pathogenic due to gain&#8208;of&#8208;function, in accordance with the previously reported mechanism in this gene (Southgate et&#160;al., <xref rid="humu23567-bib-0029" ref-type="ref">2011</xref>). Second, cysteine substitutions within EGF domains of <italic>DLL4</italic> or <italic>NOTCH1</italic> were considered to have strong evidence of pathogenicity, similar to null variants (Dietz, Saraiva, Pyeritz, Cutting, &amp; Francomano, <xref rid="humu23567-bib-0007" ref-type="ref">1992</xref>; Schrijver, Liu, Brenn, Furthmayr, &amp; Francke, <xref rid="humu23567-bib-0024" ref-type="ref">1999</xref>). Third, recurrent missense mutations affecting the same amino acid in independent cases were classified as pathogenic due to multiple occurrences. Lastly, in families where &#8805;3 individuals were available for screening, any variant with a penetrance less than 60% was classified as a variant of uncertain significance (VUS).</p></sec></sec><sec id="humu23567-sec-0060"><label>3</label><title>RESULTS</title><p>The analyzed cohort comprised 194 distinct AOS/ACC/TTLD familial or sporadic cases. Of these, 36 families were consistent with an autosomal recessive mode of inheritance, based on pedigree data or known consanguinity, while autosomal dominant inheritance was the most likely inheritance pattern in 55 families (Figure&#160;<xref rid="humu23567-fig-0001" ref-type="fig">1</xref>A). The remaining 103 probands were categorized as sporadic in the absence of any family history or known consanguinity. We provide a causal molecular explanation for the phenotype in 58/194 (30%) of AOS/ACC/TTLD probands (Table&#160;<xref rid="humu23567-tbl-0001" ref-type="table">1</xref>). Among the 63 pathogenic (or likely pathogenic) mutations in this study, 56 were distinct, or nonrecurrent, mutations and 22 mutations have not been reported to date (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Figure S1</xref>). In addition, we identified several VUS (<italic>n</italic>&#160;=&#160;14, <xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S3</xref> and <xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Figure S1</xref>). The data on novel variants have now been made available in the ClinVar database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar">https://www.ncbi.nlm.nih.gov/clinvar</ext-link>).</p><fig fig-type="Figure" xml:lang="en" id="humu23567-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Genetic architecture of AOS. (<bold>a</bold>) Distribution of inheritance pattern across our AOS cohort. AD, autosomal dominant; AR, autosomal recessive. (<bold>b</bold>) Contribution of mutations in each of the six known genes to the development of AOS in the complete cohort and in familial cases only. For each cohort, charts depict the gene distribution excluding VUS and when all VUS are considered as pathogenic, respectively. (<bold>c</bold>) Distribution of mutation categories across established AOS genes. (<bold>d</bold>) Representation of previously reported and novel pathogenic mutations in NOTCH1. Mutations identified in this study that were previously reported in AOS patients are represented on the upper part of the figure. Novel mutations are arrayed below the schematic. EGF 11&#8211;13 highlights the ligand&#8208;binding domain. Pathogenic mutations are depicted in black and VUS in red. ECD, Extracellular domain; ICD, Intracellular domain; EGF&#8208;like, epidermal growth factor&#8208;like domain; cbEGF&#8208;like, calcium&#8208;binding epidermal growth factor&#8208;like domain; LNR, Lin&#8208;12/Notch repeat; TM, transmembrane domain; RAM, RBP&#8208;Jkappa&#8208;associated module; ANK, ankyrin; TAD, transcriptional activation domain and PEST, proline (P), glutamic acid (E), serine (S), and threonine (T)&#8208;rich peptide sequence.</p></caption><graphic id="nlm-graphic-3" xlink:href="HUMU-39-1246-g001"/></fig><table-wrap id="humu23567-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Identified pathogenic mutations in six established AOS genes</p></caption><table-wrap-foot><fn id="humu23567-tbl1-note-0001"><label>a</label><p>GenBank reference sequence and version number for <italic>ARHGAP31</italic>: NM_020754.3; <italic>DLL4</italic>: NM_019074.3; <italic>DOCK6</italic>: NM_020812.3; <italic>EOGT</italic>: NM_001278689.1; <italic>NOTCH1</italic>: NM_017617.4; <italic>RBPJ</italic>: NM_005349.3; numbering is from +1 as A of the ATG initiation codon.</p></fn><fn id="humu23567-tbl1-note-0002"><label>b</label><p>This column refers to medical case reports in which clinical features observed in specific families are described.</p></fn><fn id="humu23567-tbl1-note-0003"><label>c</label><p>Mutation was found in the same family as described in this publication.</p></fn><fn id="humu23567-tbl1-note-0004"><label>d</label><p>Mutation published previously in a different family.</p></fn><fn id="humu23567-tbl1-note-0005"><label>e</label><p>Exon skipping was verified at the RNA level.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>We observed a causal mutation in 13 of the 36 families (36%) with likely autosomal recessive inheritance. These include homozygous mutations in <italic>EOGT</italic> (n&#160;=&#160;3) and <italic>DOCK6</italic> (n&#160;=&#160;7), and compound heterozygous mutations (<italic>EOGT</italic>, <italic>n</italic>&#160;=&#160;1; <italic>DOCK6</italic>, <italic>n</italic>&#160;=&#160;2). One additional case harbored a heterozygous VUS in <italic>DOCK6</italic>, but we did not detect a variant on the second allele (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S3</xref>). The remaining 22 recessive families remain unresolved after analyzing all currently known AOS genes.</p><p>In the autosomal dominant cohort, 36% (20/55) of AOS cases were directly attributable to the established AOS genes with pathogenic mutations observed in <italic>ARHGAP31</italic> (<italic>n</italic>&#160;=&#160;4), <italic>DLL4</italic> (<italic>n</italic>&#160;=&#160;5), <italic>NOTCH1</italic> (<italic>n</italic>&#160;=&#160;7), and <italic>RBPJ</italic> (<italic>n</italic>&#160;=&#160;4) (Table&#160;<xref rid="humu23567-tbl-0001" ref-type="table">1</xref>). Furthermore, we observed four VUS in <italic>NOTCH1</italic> (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S3</xref>). In one proband (Family 16), two <italic>NOTCH1</italic> missense variants were detected (p.Trp2034Arg and p.Ala2043Val). Both variants were confirmed to exist on the same allele, due to co&#8208;occurrence in the same next&#8208;generation sequencing read. These variants were not present in the healthy mother and sister. Due to the unavailability of paternal DNA, we were unable to determine whether either of these variants had occurred <italic>de novo</italic>.</p><p>In our cohort of 103 sporadic cases, the frequency of identified likely pathogenic mutations was 24%. We detected heterozygous mutations in <italic>ARHGAP31</italic> (<italic>n</italic>&#160;=&#160;2), <italic>DLL4</italic> (<italic>n</italic>&#160;=&#160;7), and <italic>NOTCH1</italic> (<italic>n</italic>&#160;=&#160;12), in addition to compound heterozygous <italic>DOCK6</italic> mutations (<italic>n</italic>&#160;=&#160;2) and homozygous <italic>EOGT</italic> mutations (<italic>n</italic>&#160;=&#160;2) (Table&#160;<xref rid="humu23567-tbl-0001" ref-type="table">1</xref>). Additionally, we observed several VUS in <italic>NOTCH1</italic> (<italic>n</italic>&#160;=&#160;6), <italic>DLL4</italic> (<italic>n</italic>&#160;=&#160;3), and <italic>DOCK6</italic> (<italic>n</italic>&#160;=&#160;1) (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S3</xref>).</p><p>Taken together, mutations in the six established AOS genes underlie less than one third of the AOS/ACC/TTLD probands in our total cohort (Figure&#160;<xref rid="humu23567-fig-0001" ref-type="fig">1</xref>B). <italic>NOTCH1</italic> is the major contributor to the AOS phenotype, both in familial and sporadic disease, harboring 10% of the mutational load in our study. Mutations in <italic>DLL4</italic> and <italic>DOCK6</italic> each represent 6% of the cases while <italic>ARHGAP31</italic>, <italic>EOGT</italic>, and <italic>RBPJ</italic> mutations account for only small proportions, underlying 3%, 3%, and 2% of cases, respectively. Among familial cases we observed an elevated mutation detection rate of 36% overall (Figure&#160;<xref rid="humu23567-fig-0001" ref-type="fig">1</xref>B). <italic>NOTCH1</italic>, <italic>DLL4</italic>, <italic>EOGT</italic>, and <italic>DOCK6</italic> harbored deleterious variation across the major mutational categories, including insertion&#8211;deletion, nonsense, splicing, and missense variants (Figure&#160;<xref rid="humu23567-fig-0001" ref-type="fig">1</xref>C). By contrast, mutations observed in <italic>ARHGAP31</italic> comprised protein&#8208;truncating mutations confined to the last exon, while all <italic>RBPJ</italic> mutations result in amino acid substitutions within a conserved DNA&#8208;binding domain (Figure&#160;<xref rid="humu23567-fig-0001" ref-type="fig">1</xref>C).</p><p>An analysis of clinical features in our cohort determined that 96% of the mutation&#8208;positive cases had scalp defects (with or without underlying skull defect), while TTLD was observed in 78% of mutation&#8208;positive cases (Table&#160;<xref rid="humu23567-tbl-0002" ref-type="table">2</xref>). Assessment of potential genotype&#8211;phenotype correlations revealed wide variability in TTLD characteristics both within and between families. Brachydactyly and hypoplastic digits or nails were observed most frequently. ACC also demonstrated wide phenotypic variability, ranging from small patches of skin lacking hair to complete absence of skin with underlying skull defect. However, there did not appear to be any gene&#8208;specific correlation with observed limb or scalp defects.</p><table-wrap id="humu23567-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Phenotype of mutation&#8208;positive AOS patients</p></caption><table-wrap-foot><fn id="humu23567-tbl2-note-0001"><p>ACC, aplasia cutis congenita; AS, aortic stenosis; ASD, atrial septal defect; AV, aortic valve; CHD, congenital heart defect; CMTC, cutis marmorata telangiectatica congenita; CoA, coarctation of the aorta; CT, Computed Tomography; IUGR, intrauterine growth restriction; MBTS, modified Blalock&#8208;Taussig shunt; MV, mitral valve; PH, portal hypertension; PDA, patent ductus arteriosus; PTA, persistent truncus arteriosus; PV, pulmonary valve; TAPVD, total anomalous pulmonary venous drainage; TOF, Tetralogy of Fallot; TTLD, terminal transverse limb defects; TVI, tricuspid valve insufficiency; VSD, ventricular septal defect; ?, unknown; &#8722;, absent; +, present</p></fn><fn id="humu23567-tbl2-note-0002"><label>a</label><p>This column refers to medical case reports in which clinical features observed in specific families are described.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>We observed a wide variety of associated cardiac features, including ASD, VSD, patent ductus arteriosus, aortic stenosis, truncus arteriosus, TOF, and valve abnormalities. Of note, cardiac features were more frequently observed in patients with a mutation in <italic>DLL4, NOTCH1</italic>, or <italic>RBPJ</italic> (&#8805;49% vs. &#8805;13%, Table&#160;<xref rid="humu23567-tbl-0002" ref-type="table">2</xref>). However, in the absence of detailed cardiac examinations for all variant carriers, it was not possible to determine firm genotype&#8211;phenotype correlations based on these data. CMTC was reported in 29% of mutation&#8208;positive patients, while other observed vascular features included defects of pulmonary or portal vasculature, abnormal branching of the carotid artery, and sinus sagittalis thrombosis (Table&#160;<xref rid="humu23567-tbl-0002" ref-type="table">2</xref>). In <italic>DOCK6</italic>&#8208;positive cases, we observed a positive correlation with the presence of brain abnormalities and/or intellectual disability, as previously described (&#8805;91% vs. &#8805;19%, Table&#160;<xref rid="humu23567-tbl-0002" ref-type="table">2</xref>) (Sukalo et&#160;al., <xref rid="humu23567-bib-0032" ref-type="ref">2015</xref>).</p></sec><sec id="humu23567-sec-0070"><label>4</label><title>DISCUSSION</title><p>Here, we have examined the genetic contribution to AOS and isolated ACC/TTLD in our extensive cohort of families ascertained through the European AOS Consortium. With the discovery of 63 mutations in the six previously established genes, including 56 distinct and 22 novel mutations, our study provides independent confirmation of a substantial role for <italic>ARHGAP31</italic>, <italic>DLL4</italic>, <italic>DOCK6</italic>, <italic>EOGT</italic>, <italic>NOTCH1</italic>, and <italic>RBPJ</italic> in AOS pathogenesis. This combined mutation screening strategy represents the largest cohort of AOS patients reported to date and, while some of the cases detailed here have been previously published in cohorts used for novel gene identification (Table&#160;<xref rid="humu23567-tbl-0001" ref-type="table">1</xref>), this comprehensive review and mutation update provides unique insight into the distribution and frequency of mutations across the wider spectrum of AOS&#8208;related disorders. The majority of identified mutations (<italic>n</italic>&#160;=&#160;41; 71%) affect genes within the Notch pathway and are therefore predicted to lead to dysregulated Notch signaling, likely through haploinsufficiency or loss&#8208;of&#8208;function (LOF) of NOTCH1, DLL4, RBPJ, or EOGT. A smaller proportion (<italic>n</italic>&#160;=&#160;17; 29%) affects the Rho GTPase regulators ARHGAP31 and DOCK6, which specifically influence the activity of RAC1 and CDC42.</p><sec id="humu23567-sec-0080"><label>4.1</label><title>Autosomal dominant AOS</title><p>Consistent with previous reports, our data confirm that <italic>NOTCH1</italic> is the major contributor to the genetic basis of autosomal dominant AOS/ACC/TTLD (Stittrich et&#160;al., <xref rid="humu23567-bib-0031" ref-type="ref">2014</xref>). In addition to 9 previously reported variants (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S4</xref>) (Southgate et&#160;al., <xref rid="humu23567-bib-0030" ref-type="ref">2015</xref>), we identified 10 novel mutations and nine VUS in the <italic>NOTCH1</italic> gene (Figure&#160;<xref rid="humu23567-fig-0001" ref-type="fig">1</xref>D; <xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S3</xref>). Protein&#8208;truncating variants are distributed across the length of the receptor and are predicted to lead to nonsense&#8208;mediated decay (NMD) of the mutant mRNA transcript. In contrast, and as discussed previously (Southgate et&#160;al., <xref rid="humu23567-bib-0030" ref-type="ref">2015</xref>), we observed a clustering of missense <italic>NOTCH1</italic> mutations around EGF&#8208;like domains 11&#8211;13, critical for ligand binding to the receptor (Hambleton et&#160;al., <xref rid="humu23567-bib-0009" ref-type="ref">2004</xref>; Luca et&#160;al., <xref rid="humu23567-bib-0017" ref-type="ref">2015</xref>). Here, we describe one novel missense mutation (p.Ala465Thr) within EGF12, which has been reported in ClinVar as likely pathogenic for an unspecified condition. We also identified a novel splice&#8208;site mutation (c.1669+5G&#160;&gt;&#160;A), confirmed by cDNA sequencing to lead to in&#8208;frame skipping of exon 10, encoding residues within EGF13&#8211;14 (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Figure S2</xref> and <xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S2</xref>). This variant has a minor allele frequency (MAF) of 4&#160;&#215;&#160;10<sup>&#8722;6</sup> in the gnomAD control database (<ext-link ext-link-type="uri" xlink:href="https://gnomad.broadinstitute.org/;">https://gnomad.broadinstitute.org/;</ext-link> V.r2.0.2). The identification of these mutations in our AOS cohort provides further confirmation of the importance of this ligand&#8208;binding region for normal human development. We also describe five cysteine&#8208;replacing or &#8208;creating mutations within other EGF&#8208;like repeat domains, of which two (p.Arg902Cys and p.Cys1094Tyr) are novel. Cysteine residues within this region form essential disulfide bonds (Dietz et&#160;al., <xref rid="humu23567-bib-0007" ref-type="ref">1992</xref>; Schrijver et&#160;al., <xref rid="humu23567-bib-0024" ref-type="ref">1999</xref>), suggesting that these mutations will most likely disrupt the tertiary structure of these domains. A number of additional missense variants were classified as VUS due to the lack of familial segregation data. Of note, the proband in Family 16 harbored two missense variants within the highly conserved ANK4 protein domain, essential for RBPJ binding (Aster et&#160;al., <xref rid="humu23567-bib-0003" ref-type="ref">2000</xref>). Taken with reports of <italic>RBPJ</italic> LOF in AOS, these findings provide a strong indication that one of these two variants is likely pathogenic.</p><p>We observed four novel mutations in <italic>DLL4</italic>, the majority of which are missense, including two cysteine substitutions (p.Cys437Ser and p.Cys466Tyr) and a substitution in EGF&#8208;like domain 3 (p.Thr317Pro). We additionally identified a novel nonsense mutation (p.Gln609*) and a c.572G&#160;&gt;&#160;A (p.Arg191His) missense mutation, recently reported in a Japanese family (Nagasaka et&#160;al., <xref rid="humu23567-bib-0021" ref-type="ref">2017</xref>). The Arg191 residue is a highly conserved residue in the DSL domain of DLL4, which stabilizes receptor&#8211;ligand binding with the NOTCH1 EGF12 domain (Luca et&#160;al., <xref rid="humu23567-bib-0017" ref-type="ref">2015</xref>). The VUS identified in <italic>DLL4</italic> include one missense variant (p.Pro267Thr), which has been reclassified here according to ACMG guidelines (Richards et&#160;al., <xref rid="humu23567-bib-0022" ref-type="ref">2015</xref>), an in&#8208;frame deletion (p.Phe89delCTT), and a potential splice&#8208;site variant (c.1240+5G&#160;&gt;&#160;C) (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S2</xref>). The observed spectrum of <italic>DLL4</italic> variation, including those identified previously (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S4</xref>), suggests that LOF is the likely molecular mechanism in <italic>DLL4</italic>&#8208;positive AOS; however, this remains to be experimentally verified.</p><p>In accordance with the previous report of <italic>RBPJ</italic> substitutions within critical DNA&#8208;binding domains (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S4</xref>) (Hassed et&#160;al., <xref rid="humu23567-bib-0010" ref-type="ref">2012</xref>), we identified four DNA&#8208;binding domain missense mutations in <italic>RBPJ</italic>, one of which (p.Lys169Glu) is recurrent, providing further evidence for LOF of this transcription factor in AOS pathogenesis. <italic>RBPJ</italic> is highly intolerant to variation, with no LOF and few missense variants observed in ExAC (<ext-link ext-link-type="uri" xlink:href="https://exac.broadinstitute.org">https://exac.broadinstitute.org</ext-link>; V.0.3.1). We detected two novel substitutions within critical DNA&#8208;binding domains. The p.Arg65Gly mutation in Family 44 affects an amino acid residue that has previously been demonstrated to bind directly to DNA (Hassed et&#160;al., <xref rid="humu23567-bib-0010" ref-type="ref">2012</xref>), while the p.Phe66Val substitution (Family 175) is considered likely pathogenic due to its position, evolutionary conservation and familial segregation. In this family, a <italic>NOTCH1</italic> variant (p.Arg1758Gly) was observed to cosegregate with disease, but was classified as a VUS due to poor conservation and its presence in control databases (MAF in gnomAD&#160;=&#160;0.00014). We additionally identified a novel p.Ser332Arg missense substitution in Family 178 (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S1</xref>). Due to ambiguity around the exact location of RBPJ domain predictions, it is unclear whether this substitution is located within the beta&#8208;trefoil DNA&#8208;binding domain; however, all <italic>RBPJ</italic> variants are consistent with a LOF disease mechanism due to likely abrogation of DNA binding.</p><p>Pathogenic mutations in <italic>ARHGAP31</italic> reported to date (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S4</xref>) are all located within the terminal exon 12, leading to premature termination of the translated protein (Isrie, Wuyts, Van Esch, &amp; Devriendt, <xref rid="humu23567-bib-0011" ref-type="ref">2014</xref>; Southgate et&#160;al., <xref rid="humu23567-bib-0029" ref-type="ref">2011</xref>). Mutation screening of <italic>ARHGAP31</italic> in our cohort identified four heterozygous protein&#8208;truncating mutations within exon 12. In addition to one novel nonsense mutation (p.Gln728*), we detected a recurrent p.Gln683* mutation in three unrelated cases, highlighting terminal exon termination mutations as a consistent feature of this gene in AOS. Microsatellite genotyping to assess potential shared haplotypes at this locus was inconclusive (data not shown). Previous analysis of the p.Gln683* mutation has demonstrated the mutant transcript escapes NMD, consistent with truncating mutations downstream of the final splice junction (Bonafede &amp; Beighton, <xref rid="humu23567-bib-0004" ref-type="ref">1979</xref>), leading to the production of a constitutively active protein and disruption of the actin cytoskeleton due to active CDC42 depletion (Southgate et&#160;al., <xref rid="humu23567-bib-0029" ref-type="ref">2011</xref>). We therefore hypothesize that other C&#8208;terminal protein&#8208;truncating mutations of ARHGAP31 will lead to a gain of protein function through a similar mechanism of NMD escape.</p></sec><sec id="humu23567-sec-0090"><label>4.2</label><title>Autosomal recessive AOS</title><p>In our autosomal recessive cohort, mutation analysis of the <italic>EOGT</italic> gene revealed five distinct mutations across six families. All variants have a very low frequency in gnomAD (maximum MAF&#160;=&#160;0.00002) and, with the exception of one family, were present in the homozygous state. In two Dutch families (Family 38 and 39), we observed an identical novel homozygous frameshift mutation (p.His27Alafs*46). Although present in the heterozygous state in gnomAD (MAF&#160;=&#160;0.00005), no homozygous genotypes were observed in European control populations. In a third family from the United Kingdom (Family 59), this mutation was present in compound heterozygosity with a second causative variant. While we were unable to formally evaluate relatedness between these families, it is notable that a recurrent <italic>EOGT</italic> mutation exists within distinct European populations.</p><p>We identified a total of 13 distinct <italic>DOCK6</italic> mutations and two VUS in <italic>DOCK6</italic>, all of which have been previously reported by our consortium (<xref rid="humu23567-supl-0001" ref-type="supplementary-material">Supporting Information Table S4</xref>) (Sukalo et&#160;al., <xref rid="humu23567-bib-0032" ref-type="ref">2015</xref>). As expected, all homozygous mutations were present in families with close parental relatedness. In our cohort of compound heterozygous mutations, four variants (c.484G&#160;&gt;&#160;T, c.788T&#160;&gt;&#160;A, c.1902_1905delGTTC, and c.4106+5G&#160;&gt;&#160;T) are unique to this consortium, while three variants have a low MAF in gnomAD (c.5939+2T&#160;&gt;&#160;C; 0.00021, c.1362_1365del; 0.00004, and c.4491+1G&#160;&gt;&#160;A; 0.00003). In two families, we only observed a single heterozygous low frequency variant. Identification of a second mutation, for example, within the noncoding region at a cryptic intronic splice site, enhancer/repressor region, or promoter region, could provide a molecular diagnosis in a limited set of patients.</p><p>Of interest, a few consanguineous families remain genetically unresolved after analyzing the coding region of the six established AOS genes. Due to the methodology used, we were unable to detect larger structural variation in these genes, which may explain a proportion of the missing heritability in AOS. Of note, linkage analysis in one consanguineous family demonstrated autozygosity across the <italic>EOGT</italic> locus but no coding mutation was identified in this gene. In several other families, genome&#8208;wide autozygosity mapping analysis has indicated the likely existence of other disease loci that require further investigation. These data strongly suggest that there are still more genes to be discovered in AOS/ACC/TTLD.</p></sec><sec id="humu23567-sec-0100"><label>4.3</label><title>Genetic architecture</title><p>A comparison of the proportion of AOS cases attributable to each particular gene observed in our current study (Figure&#160;<xref rid="humu23567-fig-0001" ref-type="fig">1</xref>B) against those previously published (Lehman et&#160;al., <xref rid="humu23567-bib-0015" ref-type="ref">2016</xref>) reveals a number of key differences. Specifically, we observed a lower frequency of mutations for all genes in our cohort. Our results indicate an overall diagnostic yield of 30%, compared to the previous report that 50%&#8211;60% of AOS cases are explained by mutations in the six established genes. This may be due to previous estimates being largely based on single reports of novel gene identification, which typically utilize highly stratified discovery cohorts that are both clinically homogeneous and mutation negative for previously characterized genes. The latter would therefore lead to an overestimation of the number of identified mutations. Of note, our cohort contains a significant number of cases and families with isolated ACC or TTLD. Given recent observations of a wide phenotypic spectrum in AOS mutation carriers, the updated diagnostic criteria proposed in 2016 (Lehman et&#160;al., <xref rid="humu23567-bib-0015" ref-type="ref">2016</xref>), which account for the presence of a pathogenic mutation in an established gene, may be more valid, leading to reclassification of nine ACC cases and one TTLD case as AOS in our cohort (data not shown). While the removal of isolated ACC/TTLD cases from our cohort does not significantly alter the diagnostic yield, it is notable that the mutation&#8208;negative sporadic cohort contains predominantly isolated ACC cases (<italic>n</italic>&#160;=&#160;27). Additionally, although we have used robust diagnostic methodologies, it is possible that our cohort may contain some cases with other genetic or nongenetic conditions.</p><p>An alternative explanation for the difference in mutation frequency between the two reports is the use of more stringent criteria for classification of identified variants in our study. We classify several variants as VUS, due to strict adherence to the ACMG guidelines. However, functional evaluation or familial segregation analyses may alter these classifications. For example, the NOTCH1 p.Asp1989Asn variant has previously been classified as pathogenic (Stittrich et&#160;al., <xref rid="humu23567-bib-0031" ref-type="ref">2014</xref>), but has since been reclassified as benign in ClinVar. Similarly, we have reclassified the NOTCH1 p.Pro407Arg and DLL4 p.Pro267Thr variants as VUS in this study (Meester et&#160;al., <xref rid="humu23567-bib-0020" ref-type="ref">2015</xref>; Southgate et&#160;al., <xref rid="humu23567-bib-0030" ref-type="ref">2015</xref>). Of note, a reclassification of all the VUS in our study as causal, would increase the diagnostic yield to 36% (Figure&#160;<xref rid="humu23567-fig-0001" ref-type="fig">1</xref>B), which is still lower than previous estimates (Lehman et&#160;al., <xref rid="humu23567-bib-0015" ref-type="ref">2016</xref>). By contrast, the use of additional gene&#8208;specific criteria for classification, as described above, may have led to an overrepresentation of pathogenic variants.</p><p>Finally, our study includes a substantial proportion of sporadic cases, which have been relatively poorly studied in previous reports favoring the use of familial cohorts for novel gene detection. A molecular diagnosis was achieved for 36% of the familial cases in our cohort, or 40% if classifying all VUS as causal (Figure&#160;<xref rid="humu23567-fig-0001" ref-type="fig">1</xref>B). Conversely, in our sporadic cases the mutation detection rate was only 24%, highlighting an increased likelihood of genetic risk factors in familial disease. Our sporadic cohort also contains nine, predominantly missense VUS. These variants would require additional supporting evidence to be reclassified as pathogenic. However, this is complicated by the absence of familial segregation data and documented reduced penetrance in this condition.</p><p>An assessment of potential genotype&#8211;phenotype correlations in our cohort revealed a few important observations. Cardiac features were more frequently observed in patients with a mutation in <italic>NOTCH1, DLL4</italic>, or <italic>RPBJ</italic>. While cardiac examination is recommended for all AOS patients, these findings indicate a specific requirement for patients with <italic>NOTCH1, DLL4</italic>, and <italic>RBPJ</italic> mutations. We also noted a positive correlation between patients with recessive mutations in <italic>DOCK6</italic> and the presence of neurological abnormalities, intrauterine growth restriction, or ocular anomalies. Finally, we observed wide phenotypic variability and incomplete penetrance. The latter was most common in <italic>NOTCH1</italic>&#8208;related AOS and to a lesser extent in <italic>ARHGAP31</italic>&#8208; and <italic>DLL4</italic>&#8208;related disease. It is likely that the level of penetrance is currently overestimated, due to segregation analysis typically being restricted to parents. Furthermore, incomplete penetrance potentially accounts for an excess of sporadic cases, a known phenomenon in AOS.</p></sec><sec id="humu23567-sec-0110"><label>4.4</label><title>Future perspectives</title><p>Despite the identification of six genes underlying AOS to date, the majority of cases (64%&#8211;70%) in our cohort remain unresolved. Several reasons that may explain this missing heritability should now be examined further. First, targeted next&#8208;generation sequencing is dependent on efficient hybridization, which did not provide full coverage of all target genes. Specifically, <italic>NOTCH1</italic> exon 1 was poorly covered using HaloPlex Target enrichment and TruSeq Custom Amplicon enrichment. While these gaps were not sequenced manually, no AOS mutations have been reported in this region of the gene to date. In addition, several target regions of <italic>DOCK6</italic> (exons 1, 2, 15, 16, 23) and <italic>RBPJ</italic> (exon 2) demonstrated reduced coverage in a subset of patients enriched with the TruSeq Custom Amplicon Panel. Second, further genetic heterogeneity of AOS is highly likely. Additional genes encoding proteins involved in NOTCH signaling or CDC42/RAC1 regulation and cytoskeleton dynamics are plausible candidates. Third, it is possible that the spectrum of AOS/ACC/TTLD disease is not uniformly monogenic. Considering the high proportion of sporadic cases for a condition that does not significantly reduce reproductive fitness, as well as the likelihood that this spectrum of disorders is a consequence of fetal vascular disruption, it is tempting to speculate that nongenetic causes or complex inheritance may be involved in the etiology of this phenotype. Fourth, the majority of samples in our cohort have not undergone copy&#8208;number variant analysis or screening of noncoding regions. Partial or complete deletion or duplication of one of the six established genes may account for approximately 20% of cases (Machado et&#160;al., <xref rid="humu23567-bib-0018" ref-type="ref">2015</xref>), but were not detected in this study due to the methodologies used. In conclusion, these data support the likely existence of additional, as yet unidentified, susceptibility genes for AOS and related disorders. Our extensive patient cohort provides opportunities for the identification of additional causal genes and functional interpretation of identified defects, with the potential to explore future therapeutic avenues in this condition.</p></sec></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="humu23567-supl-0001"><caption><p>Supporting Information</p></caption><media xlink:href="HUMU-39-1246-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="humu23567-sec-0120"><title>ACKNOWLEDGMENTS</title><p>The authors thank the participating families and the clinicians who recruited patients to the European AOS Consortium (list of clinicians is given in supplementary material). B.L.L. is senior clinical investigator of the Research Foundation&#8212;Flanders and holds a starting grant from the European Research Council (ERC&#8208;StG&#8208;2012&#8208;30972&#8208;BRAVE).&#160;J.A.N.M. and G.V. are predoctoral and postdoctoral researchers of the Research Foundation, Flanders (11Y5817N and 12D1717N, respectively). This research was supported by funding from the University of Antwerp (Lanceringsproject), the Research Foundation, Flanders (G.0221.12), The Dutch Heart Foundation (2013T093), and the Fondation Leducq (MIBAVA, Leducq 12CVD03). L.S. is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St. George's, University of London. This research was also supported by a grant from the Fritz Thyssen Stiftung (AZ 10.15.2.040MN) awarded&#160;to M.Z. We further acknowledge the use of Biomedical Research Centre (BRC) Core Facilities provided by the financial support from the Department of Health via the National Institute for Health Research comprehensive BRC award to Guy's and St Thomas&#8217; National Health Service (NHS) Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. M.A.S. was supported by the Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia (RGP&#8208;VPP&#8208;301). We are grateful to Eamonn Maher, Ezequiel Martin Rodriguez (University of Cambridge), Duncan McHale and Martin Armstrong (UCB Pharma) for supervising H.T. and enabling WES. We would also like to thank Susan Engelberg and Steffen Koppsieker for technical support.</p></ack><ack id="humu23567-sec-0130"><title>DISCLOSURE</title><p>The authors declare no conflict of interest.</p></ack><ref-list id="humu23567-bibl-0001"><title>REFERENCES</title><ref id="humu23567-bib-0001"><mixed-citation publication-type="journal" id="humu23567-cit-0001">
<string-name>
<surname>Adams</surname>, <given-names>F. H.</given-names>
</string-name>, &amp; <string-name>
<surname>Oliver</surname>, <given-names>C. P.</given-names>
</string-name> (<year>1945</year>). <article-title>Hereditary deformities in man due to arrested development</article-title>. <source xml:lang="en">Journal of Heredity</source>, <volume>36</volume>, <fpage>3</fpage>&#8211;<lpage>7</lpage>.</mixed-citation></ref><ref id="humu23567-bib-0002"><mixed-citation publication-type="journal" id="humu23567-cit-0002">
<string-name>
<surname>Adzhubei</surname>, <given-names>I. A.</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Peshkin</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Ramensky</surname>, <given-names>V. E.</given-names>
</string-name>, <string-name>
<surname>Gerasimova</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bork</surname>, <given-names>P.</given-names>
</string-name>, &#8230; <string-name>
<surname>Sunyaev</surname>, <given-names>S. R.</given-names>
</string-name> (<year>2010</year>). <article-title>A method and server for predicting damaging missense mutations</article-title>. <source xml:lang="en">Nature Methods</source>, <volume>7</volume>(<issue>4</issue>), <fpage>248</fpage>&#8211;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth0410-248</pub-id>
<pub-id pub-id-type="pmid">20354512</pub-id></mixed-citation></ref><ref id="humu23567-bib-0003"><mixed-citation publication-type="journal" id="humu23567-cit-0003">
<string-name>
<surname>Aster</surname>, <given-names>J. C.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Karnell</surname>, <given-names>F. G.</given-names>
</string-name>, <string-name>
<surname>Patriub</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Pui</surname>, <given-names>J. C.</given-names>
</string-name>, &amp; <string-name>
<surname>Pear</surname>, <given-names>W. S.</given-names>
</string-name> (<year>2000</year>). <article-title>Essential roles for ankyrin repeat and transactivation domains in induction of T&#8208;cell leukemia by notch1</article-title>. <source xml:lang="en">Molecular and Cellular Biology</source>, <volume>20</volume>(<issue>20</issue>), <fpage>7505</fpage>&#8211;<lpage>7515</lpage>.<pub-id pub-id-type="pmid">11003647</pub-id></mixed-citation></ref><ref id="humu23567-bib-0004"><mixed-citation publication-type="journal" id="humu23567-cit-0004">
<string-name>
<surname>Bonafede</surname>, <given-names>R. P.</given-names>
</string-name>, &amp; <string-name>
<surname>Beighton</surname>, <given-names>P.</given-names>
</string-name> (<year>1979</year>). <article-title>Autosomal dominant inheritance of scalp defects with ectrodactyly</article-title>. <source xml:lang="en">American Journal of Medical Genetics</source>, <volume>3</volume>(<issue>1</issue>), <fpage>35</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.1320030109</pub-id>
<pub-id pub-id-type="pmid">474617</pub-id></mixed-citation></ref><ref id="humu23567-bib-0005"><mixed-citation publication-type="journal" id="humu23567-cit-0005">
<string-name>
<surname>Bray</surname>, <given-names>S. J.</given-names>
</string-name> (<year>2006</year>). <article-title>Notch signalling: A simple pathway becomes complex</article-title>. <source xml:lang="en">Nature Reviews Molecular Cell Biology</source>, <volume>7</volume>(<issue>9</issue>), <fpage>678</fpage>&#8211;<lpage>689</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2009</pub-id>
<pub-id pub-id-type="pmid">16921404</pub-id></mixed-citation></ref><ref id="humu23567-bib-0006"><mixed-citation publication-type="journal" id="humu23567-cit-0006">
<string-name>
<surname>Cohen</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Silberstein</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Perez</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Landau</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Elbedour</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Langer</surname>, <given-names>Y.</given-names>
</string-name>, &#8230; <string-name>
<surname>Birk</surname>, <given-names>O. S.</given-names>
</string-name> (<year>2014</year>). <article-title>Autosomal recessive Adams&#8211;Oliver syndrome caused by homozygous mutation in EOGT, encoding an EGF domain&#8208;specific O&#8208;GlcNAc transferase</article-title>. <source xml:lang="en">European Journal of Human Genetics</source>, <volume>22</volume>(<issue>3</issue>), <fpage>374</fpage>&#8211;<lpage>378</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2013.159</pub-id>
<pub-id pub-id-type="pmid">23860037</pub-id></mixed-citation></ref><ref id="humu23567-bib-0040"><mixed-citation publication-type="journal" id="humu23567-cit-0040">
<string-name>
<surname>Dallapiccola</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Giannotti</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Marino</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Digilio</surname>, <given-names>C.</given-names>
</string-name>, &amp; <string-name>
<surname>Obregon</surname>, <given-names>G.</given-names>
</string-name> (<year>1992</year>). <article-title>Familial aplasia cutis congenita and coarctation of the aorta</article-title>. <source xml:lang="en">Am J Med Genet</source>, <volume>43</volume>(<issue>4</issue>), <fpage>762</fpage>&#8211;<lpage>763</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.1320430423</pub-id>
<pub-id pub-id-type="pmid">1621771</pub-id></mixed-citation></ref><ref id="humu23567-bib-0007"><mixed-citation publication-type="journal" id="humu23567-cit-0007">
<string-name>
<surname>Dietz</surname>, <given-names>H. C.</given-names>
</string-name>, <string-name>
<surname>Saraiva</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Pyeritz</surname>, <given-names>R. E.</given-names>
</string-name>, <string-name>
<surname>Cutting</surname>, <given-names>G. R.</given-names>
</string-name>, &amp; <string-name>
<surname>Francomano</surname>, <given-names>C. A.</given-names>
</string-name> (<year>1992</year>). <article-title>Clustering of fibrillin (FBN1) missense mutations in Marfan syndrome patients at cysteine residues in EGF&#8208;like domains</article-title>. <source xml:lang="en">Human Mutation</source>, <volume>1</volume>(<issue>5</issue>), <fpage>366</fpage>&#8211;<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1002/humu.1380010504</pub-id>
<pub-id pub-id-type="pmid">1301946</pub-id></mixed-citation></ref><ref id="humu23567-bib-0008"><mixed-citation publication-type="journal" id="humu23567-cit-0008">
<string-name>
<surname>Digilio</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>Marino</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Baban</surname>, <given-names>A.</given-names>
</string-name>, &amp; <string-name>
<surname>Dallapiccola</surname>, <given-names>B.</given-names>
</string-name> (<year>2015</year>). <article-title>Cardiovascular malformations in Adams&#8208;Oliver syndrome</article-title>. <source xml:lang="en">American Journal of Medical Genetics. Part A</source>, <volume>167A</volume>(<issue>5</issue>), <fpage>1175</fpage>&#8211;<lpage>1177</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.36764</pub-id>
<pub-id pub-id-type="pmid">25885069</pub-id></mixed-citation></ref><ref id="humu23567-bib-0043"><mixed-citation publication-type="journal" id="humu23567-cit-0043">
<string-name>
<surname>Girard</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Amiel</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Fabre</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Pariente</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Lyonnet</surname>, <given-names>S.</given-names>
</string-name>, &amp; <string-name>
<surname>Jacquemin</surname>, <given-names>E.</given-names>
</string-name> (<year>2005</year>). <article-title>Adams&#8208;Oliver syndrome and hepatoportal sclerosis: occasional association or common mechanism?</article-title>
<source xml:lang="en">Am J Med Genet A</source>, <volume>135</volume>(<issue>2</issue>), <fpage>186</fpage>&#8211;<lpage>189</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.30724</pub-id>
<pub-id pub-id-type="pmid">15832360</pub-id></mixed-citation></ref><ref id="humu23567-bib-0009"><mixed-citation publication-type="journal" id="humu23567-cit-0009">
<string-name>
<surname>Hambleton</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Valeyev</surname>, <given-names>N. V.</given-names>
</string-name>, <string-name>
<surname>Muranyi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Knott</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Werner</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>McMichael</surname>, <given-names>A. J.</given-names>
</string-name>, &#8230; <string-name>
<surname>Downing</surname>, <given-names>A. K.</given-names>
</string-name> (<year>2004</year>). <article-title>Structural and functional properties of the human notch&#8208;1 ligand binding region</article-title>. <source xml:lang="en">Structure (London, England)</source>, <volume>12</volume>(<issue>12</issue>), <fpage>2173</fpage>&#8211;<lpage>2183</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2004.09.012</pub-id>
</mixed-citation></ref><ref id="humu23567-bib-0010"><mixed-citation publication-type="journal" id="humu23567-cit-0010">
<string-name>
<surname>Hassed</surname>, <given-names>S. J.</given-names>
</string-name>, <string-name>
<surname>Wiley</surname>, <given-names>G. B.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>J. Y.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>W.</given-names>
</string-name>, &#8230; <string-name>
<surname>Gaffney</surname>, <given-names>P. M.</given-names>
</string-name> (<year>2012</year>). <article-title>RBPJ mutations identified in two families affected by Adams&#8211;Oliver syndrome</article-title>. <source xml:lang="en">American Journal of Human Genetics</source>, <volume>91</volume>(<issue>2</issue>), <fpage>391</fpage>&#8211;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2012.07.005</pub-id>
<pub-id pub-id-type="pmid">22883147</pub-id></mixed-citation></ref><ref id="humu23567-bib-0011"><mixed-citation publication-type="journal" id="humu23567-cit-0011">
<string-name>
<surname>Isrie</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wuyts</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Van Esch</surname>, <given-names>H.</given-names>
</string-name>, &amp; <string-name>
<surname>Devriendt</surname>, <given-names>K.</given-names>
</string-name> (<year>2014</year>). <article-title>Isolated terminal limb reduction defects: Extending the clinical spectrum of Adams&#8211;Oliver syndrome and ARHGAP31 mutations</article-title>. <source xml:lang="en">American Journal of Medical Genetics. Part A</source>, <volume>164A</volume>(<issue>6</issue>), <fpage>1576</fpage>&#8211;<lpage>1579</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.36486</pub-id>
<pub-id pub-id-type="pmid">24668619</pub-id></mixed-citation></ref><ref id="humu23567-bib-0012"><mixed-citation publication-type="journal" id="humu23567-cit-0012">
<string-name>
<surname>Kircher</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Witten</surname>, <given-names>D. M.</given-names>
</string-name>, <string-name>
<surname>Jain</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>O'Roak</surname>, <given-names>B. J.</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>, <given-names>G. M.</given-names>
</string-name>, &amp; <string-name>
<surname>Shendure</surname>, <given-names>J.</given-names>
</string-name> (<year>2014</year>). <article-title>A general framework for estimating the relative pathogenicity of human genetic variants</article-title>. <source xml:lang="en">Nature Genetics</source>, <volume>46</volume>(<issue>3</issue>), <fpage>310</fpage>&#8211;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2892</pub-id>
<pub-id pub-id-type="pmid">24487276</pub-id></mixed-citation></ref><ref id="humu23567-bib-0013"><mixed-citation publication-type="journal" id="humu23567-cit-0013">
<string-name>
<surname>Kumar</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Henikoff</surname>, <given-names>S.</given-names>
</string-name>, &amp; <string-name>
<surname>Ng</surname>, <given-names>P. C.</given-names>
</string-name> (<year>2009</year>). <article-title>Predicting the effects of coding non&#8208;synonymous variants on protein function using the SIFT algorithm</article-title>. <source xml:lang="en">Nature Protocols</source>, <volume>4</volume>(<issue>7</issue>), <fpage>1073</fpage>&#8211;<lpage>1082</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2009.86</pub-id>
<pub-id pub-id-type="pmid">19561590</pub-id></mixed-citation></ref><ref id="humu23567-bib-0014"><mixed-citation publication-type="journal" id="humu23567-cit-0014">
<string-name>
<surname>Lehman</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Stittrich</surname>, <given-names>A. B.</given-names>
</string-name>, <string-name>
<surname>Glusman</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Zong</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Eydoux</surname>, <given-names>P.</given-names>
</string-name>, &#8230; <string-name>
<surname>Patel</surname>, <given-names>M.</given-names>
</string-name> (<year>2014</year>). <article-title>Diffuse angiopathy in Adams&#8211;Oliver syndrome associated with truncating DOCK6 mutations</article-title>. <source xml:lang="en">American Journal of Medical Genetics. Part A</source>, <volume>164A</volume>(<issue>10</issue>), <fpage>2656</fpage>&#8211;<lpage>2662</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.36685</pub-id>
<pub-id pub-id-type="pmid">25091416</pub-id></mixed-citation></ref><ref id="humu23567-bib-0015"><mixed-citation publication-type="book" id="humu23567-cit-0015">
<string-name>
<surname>Lehman</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Wuyts</surname>, <given-names>W.</given-names>
</string-name>, &amp; <string-name>
<surname>Patel</surname>, <given-names>M. S.</given-names>
</string-name> (<year>2016</year>). <chapter-title>Adams&#8211;Oliver syndrome</chapter-title> In <person-group person-group-type="editor"><name><surname>Pagon</surname><given-names>R. A.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Adam</surname><given-names>M. P.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Ardinger</surname><given-names>H. H.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Wallace</surname><given-names>S. E.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Amemiya</surname><given-names>A.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Bean</surname><given-names>L. J. H.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Bird</surname><given-names>T. D.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Ledbetter</surname><given-names>N.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Mefford</surname><given-names>H. C.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Smith</surname><given-names>R. J. H.</given-names></name></person-group>, &amp; <person-group person-group-type="editor"><name><surname>Stephens</surname><given-names>K.</given-names></name></person-group> (Eds.), <source xml:lang="en">GeneReviews(R)</source>. <publisher-loc>Seattle, WA</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name>.</mixed-citation></ref><ref id="humu23567-bib-0016"><mixed-citation publication-type="journal" id="humu23567-cit-0016">
<string-name>
<surname>Liu</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Jian</surname>, <given-names>X.</given-names>
</string-name>, &amp; <string-name>
<surname>Boerwinkle</surname>, <given-names>E.</given-names>
</string-name> (<year>2011</year>). <article-title>dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions</article-title>. <source xml:lang="en">Human Mutation</source>, <volume>32</volume>(<issue>8</issue>), <fpage>894</fpage>&#8211;<lpage>899</lpage>. <pub-id pub-id-type="doi">10.1002/humu.21517</pub-id>
<pub-id pub-id-type="pmid">21520341</pub-id></mixed-citation></ref><ref id="humu23567-bib-0017"><mixed-citation publication-type="journal" id="humu23567-cit-0017">
<string-name>
<surname>Luca</surname>, <given-names>V. C.</given-names>
</string-name>, <string-name>
<surname>Jude</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Pierce</surname>, <given-names>N. W.</given-names>
</string-name>, <string-name>
<surname>Nachury</surname>, <given-names>M. V.</given-names>
</string-name>, <string-name>
<surname>Fischer</surname>, <given-names>S.</given-names>
</string-name>, &amp; <string-name>
<surname>Garcia</surname>, <given-names>K. C.</given-names>
</string-name> (<year>2015</year>). <article-title>Structural biology. Structural basis for Notch1 engagement of Delta&#8208;like 4</article-title>. <source xml:lang="en">Science</source>, <volume>347</volume>(<issue>6224</issue>), <fpage>847</fpage>&#8211;<lpage>853</lpage>. <pub-id pub-id-type="doi">10.1126/science.1261093</pub-id>
<pub-id pub-id-type="pmid">25700513</pub-id></mixed-citation></ref><ref id="humu23567-bib-0018"><mixed-citation publication-type="journal" id="humu23567-cit-0018">
<string-name>
<surname>Machado</surname>, <given-names>R. D.</given-names>
</string-name>, <string-name>
<surname>Southgate</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Eichstaedt</surname>, <given-names>C. A.</given-names>
</string-name>, <string-name>
<surname>Aldred</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Austin</surname>, <given-names>E. D.</given-names>
</string-name>, <string-name>
<surname>Best</surname>, <given-names>D. H.</given-names>
</string-name>, &#8230; <string-name>
<surname>Grunig</surname>, <given-names>E.</given-names>
</string-name> (<year>2015</year>). <article-title>Pulmonary arterial hypertension: A current perspective on established and emerging molecular genetic defects</article-title>. <source xml:lang="en">Human Mutation</source>, <volume>36</volume>(<issue>12</issue>), <fpage>1113</fpage>&#8211;<lpage>1127</lpage>. <pub-id pub-id-type="doi">10.1002/humu.22904</pub-id>
<pub-id pub-id-type="pmid">26387786</pub-id></mixed-citation></ref><ref id="humu23567-bib-0019"><mixed-citation publication-type="journal" id="humu23567-cit-0019">
<string-name>
<surname>Martinez&#8208;Frias</surname>, <given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Arroyo Carrera</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Munoz&#8208;Delgado</surname>, <given-names>N. J.</given-names>
</string-name>, <string-name>
<surname>Nieto Conde</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Rodriguez&#8208;Pinilla</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Urioste Azcorra</surname>, <given-names>M.</given-names>
</string-name>, &#8230; <string-name>
<surname>Garcia Alix</surname>, <given-names>A.</given-names>
</string-name> (<year>1996</year>). <article-title>[The Adams&#8211;Oliver syndrome in Spain: The epidemiological aspects]</article-title>. <source xml:lang="en">Anales Espanoles De Pediatria</source>, <volume>45</volume>(<issue>1</issue>), <fpage>57</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">8849132</pub-id></mixed-citation></ref><ref id="humu23567-bib-0020"><mixed-citation publication-type="journal" id="humu23567-cit-0020">
<string-name>
<surname>Meester</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Southgate</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Stittrich</surname>, <given-names>A. B.</given-names>
</string-name>, <string-name>
<surname>Venselaar</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Beekmans</surname>, <given-names>S. J.</given-names>
</string-name>, <string-name>
<surname>den Hollander</surname>, <given-names>N.</given-names>
</string-name>, &#8230; <string-name>
<surname>Wuyts</surname>, <given-names>W.</given-names>
</string-name> (<year>2015</year>). <article-title>Heterozygous loss&#8208;of&#8208;function mutations in DLL4 cause Adams&#8211;Oliver syndrome</article-title>. <source xml:lang="en">American Journal of Human Genetics</source>, <volume>97</volume>(<issue>3</issue>), <fpage>475</fpage>&#8211;<lpage>482</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2015.07.015</pub-id>
<pub-id pub-id-type="pmid">26299364</pub-id></mixed-citation></ref><ref id="humu23567-bib-0021"><mixed-citation publication-type="journal" id="humu23567-cit-0021">
<string-name>
<surname>Nagasaka</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Taniguchi&#8208;Ikeda</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Inagaki</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Ouchi</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Kurokawa</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Yamana</surname>, <given-names>K.</given-names>
</string-name>, &#8230; <string-name>
<surname>Iijima</surname>, <given-names>K.</given-names>
</string-name> (<year>2017</year>). <article-title>Novel missense mutation in DLL4 in a Japanese sporadic case of Adams&#8211;Oliver syndrome</article-title>. <source xml:lang="en">Journal of Human Genetics</source>, <pub-id pub-id-type="doi">10.1038/jhg.2017.48</pub-id>
</mixed-citation></ref><ref id="humu23567-bib-0041"><mixed-citation publication-type="journal" id="humu23567-cit-0041">
<string-name>
<surname>Orstavik</surname>, <given-names>K. H.</given-names>
</string-name>, <string-name>
<surname>Stromme</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Spetalen</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Flage</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Westvik</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Vesterhus</surname>, <given-names>P.</given-names>
</string-name>, &amp; <string-name>
<surname>Skjeldal</surname>, <given-names>O.</given-names>
</string-name> (<year>1995</year>). <article-title>Aplasia cutis congenita associated with limb, eye, and brain anomalies in sibs: a variant of the Adams&#8208;Oliver syndrome?</article-title>
<source xml:lang="en">Am J Med Genet</source>, <volume>59</volume>(<issue>1</issue>), <fpage>92</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.1320590118</pub-id>
<pub-id pub-id-type="pmid">8849019</pub-id></mixed-citation></ref><ref id="humu23567-bib-0042"><mixed-citation publication-type="journal" id="humu23567-cit-0042">
<string-name>
<surname>Prothero</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Nicholl</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>, <given-names>J.</given-names>
</string-name>, &amp; <string-name>
<surname>Wakeling</surname>, <given-names>E. L.</given-names>
</string-name> (<year>2007</year>). <article-title>Aplasia cutis congenita, terminal limb defects and falciform retinal folds: confirmation of a distinct syndrome of vascular disruption</article-title>. <source xml:lang="en">Clin Dysmorphol</source>, <volume>16</volume>(<issue>1</issue>), <fpage>39</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1097/MCD.0b013e328010b81c</pub-id>
<pub-id pub-id-type="pmid">17159513</pub-id></mixed-citation></ref><ref id="humu23567-bib-0022"><mixed-citation publication-type="journal" id="humu23567-cit-0022">
<string-name>
<surname>Richards</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Aziz</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Bale</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Bick</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Das</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Gastier&#8208;Foster</surname>, <given-names>J.</given-names>
</string-name>, &#8230; <string-name>
<surname>Committee</surname>, <given-names>A. L. Q. A.</given-names>
</string-name> (<year>2015</year>). <article-title>Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology</article-title>. <source xml:lang="en">Genetics in Medicine</source>, <volume>17</volume>(<issue>5</issue>), <fpage>405</fpage>&#8211;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id>
<pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation></ref><ref id="humu23567-bib-0023"><mixed-citation publication-type="journal" id="humu23567-cit-0023">
<string-name>
<surname>Sakaidani</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Ichiyanagi</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Saito</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Nomura</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Ito</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Nishio</surname>, <given-names>Y.</given-names>
</string-name>, &#8230; <string-name>
<surname>Okajima</surname>, <given-names>T.</given-names>
</string-name> (<year>2012</year>). <article-title>O&#8208;linked&#8208;N&#8208;acetylglucosamine modification of mammalian Notch receptors by an atypical O&#8208;GlcNAc transferase Eogt1</article-title>. <source xml:lang="en">Biochemical and Biophysical Research Communications</source>, <volume>419</volume>(<issue>1</issue>), <fpage>14</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2012.01.098</pub-id>
<pub-id pub-id-type="pmid">22310717</pub-id></mixed-citation></ref><ref id="humu23567-bib-0024"><mixed-citation publication-type="journal" id="humu23567-cit-0024">
<string-name>
<surname>Schrijver</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Brenn</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Furthmayr</surname>, <given-names>H.</given-names>
</string-name>, &amp; <string-name>
<surname>Francke</surname>, <given-names>U.</given-names>
</string-name> (<year>1999</year>). <article-title>Cysteine substitutions in epidermal growth factor&#8208;like domains of fibrillin&#8208;1: Distinct effects on biochemical and clinical phenotypes</article-title>. <source xml:lang="en">American Journal of Human Genetics</source>, <volume>65</volume>(<issue>4</issue>), <fpage>1007</fpage>&#8211;<lpage>1020</lpage>. <pub-id pub-id-type="doi">10.1086/302582</pub-id>
<pub-id pub-id-type="pmid">10486319</pub-id></mixed-citation></ref><ref id="humu23567-bib-0025"><mixed-citation publication-type="journal" id="humu23567-cit-0025">
<string-name>
<surname>Schwarz</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>, <given-names>D. N.</given-names>
</string-name>, <string-name>
<surname>Schuelke</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Seelow</surname>, <given-names>D.</given-names>
</string-name> (<year>2014</year>). <article-title>MutationTaster2: Mutation prediction for the deep&#8208;sequencing age</article-title>. <source xml:lang="en">Nature Methods</source>, <volume>11</volume>(<issue>4</issue>), <fpage>361</fpage>&#8211;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2890</pub-id>
<pub-id pub-id-type="pmid">24681721</pub-id></mixed-citation></ref><ref id="humu23567-bib-0026"><mixed-citation publication-type="journal" id="humu23567-cit-0026">
<string-name>
<surname>Shaheen</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Aglan</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Keppler&#8208;Noreuil</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Faqeih</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Ansari</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Horton</surname>, <given-names>K.</given-names>
</string-name>, &#8230; <string-name>
<surname>Alkuraya</surname>, <given-names>F. S.</given-names>
</string-name> (<year>2013</year>). <article-title>Mutations in EOGT confirm the genetic heterogeneity of autosomal&#8208;recessive Adams&#8211;Oliver syndrome</article-title>. <source xml:lang="en">American Journal of Human Genetics</source>, <volume>92</volume>(<issue>4</issue>), <fpage>598</fpage>&#8211;<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2013.02.012</pub-id>
<pub-id pub-id-type="pmid">23522784</pub-id></mixed-citation></ref><ref id="humu23567-bib-0027"><mixed-citation publication-type="journal" id="humu23567-cit-0027">
<string-name>
<surname>Shaheen</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Faqeih</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Sunker</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Morsy</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Al&#8208;Sheddi</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Shamseldin</surname>, <given-names>H. E.</given-names>
</string-name>, &#8230; <string-name>
<surname>Alkuraya</surname>, <given-names>F. S.</given-names>
</string-name> (<year>2011</year>). <article-title>Recessive mutations in DOCK6, encoding the guanidine nucleotide exchange factor DOCK6, lead to abnormal actin cytoskeleton organization and Adams&#8211;Oliver syndrome</article-title>. <source xml:lang="en">American Journal of Human Genetics</source>, <volume>89</volume>(<issue>2</issue>), <fpage>328</fpage>&#8211;<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2011.07.009</pub-id>
<pub-id pub-id-type="pmid">21820096</pub-id></mixed-citation></ref><ref id="humu23567-bib-0028"><mixed-citation publication-type="journal" id="humu23567-cit-0028">
<string-name>
<surname>Snape</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Ruddy</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Zenker</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wuyts</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Whiteford</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>, <given-names>D.</given-names>
</string-name>, &#8230; <string-name>
<surname>Trembath</surname>, <given-names>R. C.</given-names>
</string-name> (<year>2009</year>). <article-title>The spectra of clinical phenotypes in aplasia cutis congenita and terminal transverse limb defects</article-title>. <source xml:lang="en">American Journal of Medical Genetics. Part A</source>, <volume>149A</volume>(<issue>8</issue>), <fpage>1860</fpage>&#8211;<lpage>1881</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.32708</pub-id>
<pub-id pub-id-type="pmid">19610107</pub-id></mixed-citation></ref><ref id="humu23567-bib-0029"><mixed-citation publication-type="journal" id="humu23567-cit-0029">
<string-name>
<surname>Southgate</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Machado</surname>, <given-names>R. D.</given-names>
</string-name>, <string-name>
<surname>Snape</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Primeau</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Dafou</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Ruddy</surname>, <given-names>D. M.</given-names>
</string-name>, &#8230; <string-name>
<surname>Trembath</surname>, <given-names>R. C.</given-names>
</string-name> (<year>2011</year>). <article-title>Gain&#8208;of&#8208;function mutations of ARHGAP31, a Cdc42/Rac1 GTPase regulator, cause syndromic cutis aplasia and limb anomalies</article-title>. <source xml:lang="en">American Journal of Human Genetics</source>, <volume>88</volume>(<issue>5</issue>), <fpage>574</fpage>&#8211;<lpage>585</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2011.04.013</pub-id>
<pub-id pub-id-type="pmid">21565291</pub-id></mixed-citation></ref><ref id="humu23567-bib-0030"><mixed-citation publication-type="journal" id="humu23567-cit-0030">
<string-name>
<surname>Southgate</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Sukalo</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Karountzos</surname>, <given-names>A. S.</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>, <given-names>E. J.</given-names>
</string-name>, <string-name>
<surname>Collinson</surname>, <given-names>C. S.</given-names>
</string-name>, <string-name>
<surname>Ruddy</surname>, <given-names>D.</given-names>
</string-name>, &#8230; <string-name>
<surname>Trembath</surname>, <given-names>R. C.</given-names>
</string-name> (<year>2015</year>). <article-title>Haploinsufficiency of the NOTCH1 receptor as a cause of Adams&#8211;Oliver syndrome with variable cardiac anomalies</article-title>. <source xml:lang="en">Circulation. Cardiovascular Genetics</source>, <volume>8</volume>(<issue>4</issue>), <fpage>572</fpage>&#8211;<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCGENETICS.115.001086</pub-id>
<pub-id pub-id-type="pmid">25963545</pub-id></mixed-citation></ref><ref id="humu23567-bib-0031"><mixed-citation publication-type="journal" id="humu23567-cit-0031">
<string-name>
<surname>Stittrich</surname>, <given-names>A. B.</given-names>
</string-name>, <string-name>
<surname>Lehman</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bodian</surname>, <given-names>D. L.</given-names>
</string-name>, <string-name>
<surname>Ashworth</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zong</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>H.</given-names>
</string-name>, &#8230; <string-name>
<surname>Patel</surname>, <given-names>M. S.</given-names>
</string-name> (<year>2014</year>). <article-title>Mutations in NOTCH1 cause Adams&#8211;Oliver syndrome</article-title>. <source xml:lang="en">American Journal of Human Genetics</source>, <volume>95</volume>(<issue>3</issue>), <fpage>275</fpage>&#8211;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2014.07.011</pub-id>
<pub-id pub-id-type="pmid">25132448</pub-id></mixed-citation></ref><ref id="humu23567-bib-0032"><mixed-citation publication-type="journal" id="humu23567-cit-0032">
<string-name>
<surname>Sukalo</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tilsen</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Kayserili</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Muller</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Tuysuz</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Ruddy</surname>, <given-names>D. M.</given-names>
</string-name>, &#8230; <string-name>
<surname>Zenker</surname>, <given-names>M.</given-names>
</string-name> (<year>2015</year>). <article-title>DOCK6 mutations are responsible for a distinct autosomal&#8208;recessive variant of Adams&#8211;Oliver syndrome associated with brain and eye anomalies</article-title>. <source xml:lang="en">Human Mutation</source>, <volume>36</volume>(<issue>11</issue>), <fpage>1112</fpage>
<pub-id pub-id-type="doi">10.1002/humu.22830</pub-id>
<pub-id pub-id-type="pmid">26457590</pub-id></mixed-citation></ref><ref id="humu23567-bib-0044"><mixed-citation publication-type="journal" id="humu23567-cit-0044">
<string-name>
<surname>Verdyck</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Blaumeiser</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Holder&#8208;Espinasse</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Van Hul</surname>, <given-names>W.</given-names>
</string-name>, &amp; <string-name>
<surname>Wuyts</surname>, <given-names>W.</given-names>
</string-name> (<year>2006</year>). <article-title>Adams&#8208;Oliver syndrome: clinical description of a four&#8208;generation family and exclusion of five candidate genes</article-title>. <source xml:lang="en">Clin Genet</source>, <volume>69</volume>(<issue>1</issue>), <fpage>86</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-0004.2006.00552.x</pub-id>
<pub-id pub-id-type="pmid">16451141</pub-id></mixed-citation></ref><ref id="humu23567-bib-0045"><mixed-citation publication-type="journal" id="humu23567-cit-0045">
<string-name>
<surname>Verdyck</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Holder&#8208;Espinasse</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hul</surname>, <given-names>W. V.</given-names>
</string-name>, &amp; <string-name>
<surname>Wuyts</surname>, <given-names>W.</given-names>
</string-name> (<year>2003</year>). <article-title>Clinical and molecular analysis of nine families with Adams&#8208;Oliver syndrome</article-title>. <source xml:lang="en">Eur J Hum Genet</source>, <volume>11</volume>(<issue>6</issue>), <fpage>457</fpage>&#8211;<lpage>463</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejhg.5200980</pub-id>
<pub-id pub-id-type="pmid">12774039</pub-id></mixed-citation></ref><ref id="humu23567-bib-0033"><mixed-citation publication-type="journal" id="humu23567-cit-0033">
<string-name>
<surname>Wang</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Hakonarson</surname>, <given-names>H.</given-names>
</string-name> (<year>2010</year>). <article-title>ANNOVAR: Functional annotation of genetic variants from high&#8208;throughput sequencing data</article-title>. <source xml:lang="en">Nucleic Acids Research</source>, <volume>38</volume>(<issue>16</issue>), <fpage>e164</fpage>.<pub-id pub-id-type="pmid">20601685</pub-id></mixed-citation></ref></ref-list></back></article>